Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions
Dry Age-related Macular Degeneration
Interventions
DEVICE

Valeda PBM treatment

The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.

DEVICE

Valeda Sham treatment

The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.

Trial Locations (8)

55131

Universitaetsmedizin Mainz- Augenklinik, Mainz

79106

Universitätsklinikum Freiburg- Klinik für Augenheilkunde, Freiburg im Breisgau

Unknown

Institut ophtalmologique de l'Ouest- Clinique jules VERNE, Nantes

Klinik fur Ophthalmologie, Universitatsklinikum Schleswig-Holstein, Kiel

Osprdalr San Raffaele, Milan

Institut Català de Retina, Barcelona

NR31 6LA

James Paget University, Great Yarmouth

PE3 9GZ

Peterborough City Hospital, Peterborough

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LumiThera, Inc.

INDUSTRY